Patent · US Active

Antibodies against ILT2

US11236162B2 · kind B2 · utility

2Cited by

1References

14Claims

0Family size

Assignee

Biond Biologies Ltd. · IL

Inventors

Ilana MANDEL · Carmiel, IL
Tsuri Peretz · Kiryat Tivon, IL
Dana HAVES ZIV · Carmiel, IL
Ilana Goldshtein · Misgav Am, IL
Dror ALISHEKEVITZ · Kiryat Tivon, IL
Anna FRIDMAN-DROR · Yarkona, IL
Motti HAKIM · Gazit, IL
Avidor Shulman · Rakefet, IL
Yair SAPIR · Manof, IL
Tehila BEN-MOSHE · Koranit, IL

Key dates

Filing date	Apr 6, 2021
Grant date	Feb 1, 2022
Priority date	—
Expiry date	Apr 6, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.